| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Servicio Patologia Digestiva, Hospital General Universitario de Valencia,
Valencia, Spain.
2 CT and MRI Unit, Hospital General Universitario de Valencia, Avda. Tres Cruces
s/n, Valencia, Valencia, Spain, 46014.
3 Servicio de Gastroenterologia, Hospital Clinico Universitario de Valencia,
Valencia, Spain.
4 Servicio de Diagnostico por Imagen, Hospital General Universitario de
Valencia, Valencia, Spain.
OBJECTIVE. We wanted to assess the capability of MRI to quantitatively evaluate the therapeutic response to Crohn's disease (CD) relapse.
SUBJECTS AND METHODS. Twenty patients with histologically proven CD were prospectively evaluated with MRI and ileocolonoscopy over a 2-year period. The MRI protocol included axial and coronal T2-weighted and contrast-enhanced T1-weighted sequences. MRI examinations were performed twice, once during an acute relapse of CD and the other at clinical remission. The terminal ileum and colon were divided into six segments/patient, and the endoscopy and histology findings were considered the standard of reference. These were compared on a segmental basis with the quantitative MRI findings regarding wall thickness and contrast enhancement. The results obtained in active and remission CD phases were likewise compared with the findings in 10 control subjects who underwent complete ileocolonoscopy for other reasons and had no pathological findings on ileocolonoscopy.
RESULTS. Fifty three of 120 (44.2%) bowel segments showed pathologic changes on endoscopy and histology consistent with CD in active phase. On changing from the active disease phase to clinical remission, a significant decrease was observed in the wall thickness and contrast enhancement of the affected bowel wall. In the active phase of CD, the pathologic bowel segments presented with significantly greater contrast enhancement and wall thickness values compared with the healthy segments of CD and controls. On converting clinically into remission, contrast enhancement tended to normalize, whereas bowel wall thickness remained increased compared with the controls.
CONCLUSION. MRI is able to detect pathologic bowel segments in CD, as it allows the measurement of significant variations in wall thickness and contrast enhancement on changing from the active phase of the disease to remission.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Sinha, P. Rajiah, P. Murphy, P. Hawker, and S. Sanders Utility of High-Resolution MR Imaging in Demonstrating Transmural Pathologic Changes in Crohn Disease RadioGraphics, October 1, 2009; 29(6): 1847 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Lee, A. Y. Kim, S.-K. Yang, J.-W. Chung, S. Y. Kim, S. H. Park, and H. K. Ha Crohn Disease of the Small Bowel: Comparison of CT Enterography, MR Enterography, and Small-Bowel Follow-Through as Diagnostic Techniques Radiology, June 1, 2009; 251(3): 751 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Hara, S. Alam, R. I. Heigh, S. R. Gurudu, J. G. Hentz, and J. A. Leighton Using CT Enterography to Monitor Crohn's Disease Activity: A Preliminary Study Am. J. Roentgenol., June 1, 2008; 190(6): 1512 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sinha, C. Nwokolo, and P. D Murphy Magnetic resonance imaging in Crohn's disease BMJ, February 2, 2008; 336(7638): 273 - 276. [Full Text] [PDF]
|
|
|
|
|
|
F. Booya, J. G. Fletcher, J. E. Huprich, J. M. Barlow, C. D. Johnson, J. L. Fidler, C. A. Solem, W. J. Sandborn, E. V. Loftus Jr, and W. S. Harmsen Active Crohn Disease: CT Findings and Interobserver Agreement for Enteric Phase CT Enterography Radiology, December 1, 2006; 241(3): 787 - 795. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
